SEC Form 4 · accession 0001193125-26-266279
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen W Webster
Director
Period of report
Jun 8, 2026
Accepted (ET)
Jun 10, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001035354
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $11.00 | Jun 8, 2026 | A | 13,587 | A | — | Jun 8, 2036 | Common Stock | 13,587 | 13,587 | D |
Explanation of responses
- F1The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.